Human Papillomavirus Infection in Ulaanbaatar, Mongolia: A Population-Based Study

Data on human papillomavirus (HPV) and cervical cancer burden in Central Asia are scarce. To investigate HPV infection in Ulaanbaatar, the capital of Mongolia, we obtained cervical cell specimens from a population of 969 women ages 15 to 59 years. DNA of 44 HPV types was detected using a GP5+/6+ PCR-based assay. Seropositivity for L1 proteins of HPV 16, 18, 31, 33, 45, 52, and 58 was assessed using multiplex HPV serology. Cytologic abnormalities were detected in 127 women (13.1%), among whom 6 cervical intraepithelial neoplasia grade 3 and 2 invasive cervical cancers were diagnosed. Overall HPV DNA prevalence was 35.0%, being highest (48.5%) in women ages <25 years. High-risk types were detected in 24.5% of women. HPV DNA prevalence declined with age but remained >25% in all age groups. HPV seroprevalence was also very high (38.0%) and increased steadily from 33.2% to 48.9% in women ages <25 and 50 to 59 years, respectively. However, the proportion of women positive for both HPV markers of any individual HPV type was low. HPV16 was the most frequently detected type by PCR (6.1%), serology (23.0%), or both (2.1%). Lifetime number of sexual partners and induced abortions were shown to be directly associated with HPV DNA and/or seroprevalence. HPV prevalence in Ulaanbaatar was higher than that detected by similar HPV testing protocols in other populations in Asia or elsewhere and would suggest an important, yet unquantified, cervical cancer burden. Improving cervical cancer prevention, through screening and HPV vaccination, is an important public health issue for Mongolia. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1731–8)

[1]  S. Franceschi,et al.  Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea , 2007, Cancer Epidemiology Biomarkers & Prevention.

[2]  R. Burk,et al.  Papillomavirus vaccines in perspective , 2007, The Lancet.

[3]  C. Chiu,et al.  Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  M. Lehtinen,et al.  Seroprevalence atlas of infections with oncogenic and non‐oncogenic human papillomaviruses in Finland in the 1980s and 1990s , 2006, International journal of cancer.

[5]  S. Franceschi,et al.  Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide , 2006, International journal of cancer.

[6]  S. Franceschi,et al.  Reproductive Factors, Oral Contraceptive Use, and Human Papillomavirus Infection: Pooled Analysis of the IARC HPV Prevalence Surveys , 2006, Cancer Epidemiology Biomarkers & Prevention.

[7]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[8]  Helen Trottier,et al.  Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. , 2006, American journal of epidemiology.

[9]  S. Franceschi,et al.  Sexual Behavior, Condom Use, and Human Papillomavirus: Pooled Analysis of the IARC Human Papillomavirus Prevalence Surveys , 2006, Cancer Epidemiology Biomarkers & Prevention.

[10]  Markus F Templin,et al.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.

[11]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[12]  A. Alberg,et al.  Gender Differences in Sexual Biomarkers and Behaviors Associated With Human Papillomavirus-16, −18, and −33 Seroprevalence , 2004, Sexually transmitted diseases.

[13]  M. Sherman,et al.  Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica , 2003, British Journal of Cancer.

[14]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[15]  P. Coursaget,et al.  Prevalence of human papillomavirus infection in women in Busan, South Korea , 2003, International journal of cancer.

[16]  W. Reeves,et al.  Seroprevalence of human papillomavirus type 16 infection in the United States. , 2002, The Journal of infectious diseases.

[17]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[18]  P. Snijders,et al.  GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes , 2002, Journal of Clinical Microbiology.

[19]  P. Coursaget,et al.  Prevalence of Anti-Human Papillomavirus Type 16, 18, 31, and 58 Virus-Like Particles in Women in the General Population and in Prostitutes , 2001, Journal of Clinical Microbiology.

[20]  A. Giuliano,et al.  Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  S. Garland,et al.  Prevalence of Sexually Transmitted Infections (Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Human Papillomavirus) in Female Attendees of a Sexually Transmitted Diseases Clinic in Ulaanbaatar, Mongolia , 2001, Infectious diseases in obstetrics and gynecology.

[22]  J. Walboomers,et al.  Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age‐related patterns for high‐risk and low‐risk types , 2000, International journal of cancer.

[23]  S. Vermund,et al.  Sexually transmitted diseases in Ulaanbaatar, Mongolia , 1998, International journal of STD & AIDS.

[24]  B. Dorzhgotov,et al.  Malignant tumor morbidity in Mongolian People's Republic. , 1989, La Sante publique.

[25]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[26]  Richard Doll,et al.  Cancer incidence in five continents : a technical report , 1966 .